According to a new report, the market for in vitro toxicology is expected to grow to more than $300 million by 2005
Secondary Screening 2003 presents a quantitative market model segmented by re-screening, toxicology, and ADME.
It includes detailed assessment of competitive landscape, including 40 company evaluations, and analysis of key drivers and trends in a complex and dynamic industry.
90% of compounds fail in drug development because of four reasons.
41% of those fail because of poor ADME, 31% because of insufficient efficacy, 22% because of toxicity, and only 6% because of market and/or commercialisation complications.
The earlier in the development process that an inadequate compound can be removed, the less time and money wasted, usually on the order of five to ten years and hundreds of millions of dollars.
The triage process thus represents a large opportunity with significant unmet needs, and new technologies are defining and expanding this market.
Triage starts immediately after primary high-throughput screening, and the market opportunity for re-screening of hits is approximately $190 million worldwide and expected to grow to more than $250 million by 2005.
The market opportunities for toxicology and ADME currently total approximately $3 billion, most of which is spent on animal studies.
The market for in vitro toxicology testing, the segment within secondary screening, is approximately $200 million and expected to grow more than $300 million by 2005.
The growth within all three of these segments is driven by a diverse set of new technologies, including high-content screening platforms and cellular models of toxicology and metabolism.
Most of these technologies are distributed across more than 40 companies, but a significant amount of industry consolidation is expected over the next two years to integrate instruments, reagents, and informatics/data management solutions.
Navigating this dynamic competitive landscape and emerging market requires business intelligence.
Secondary Screening 2003 is produced by Select Biosciences, an international biotechnology business consulting firm that specialises in drug discovery technologies.
